Pankreaserkrankungen und Therapie

Pankreaserkrankungen und Therapie
Offener Zugang

ISSN: 2165-7092


Updating the Classification of Type 2 Diabetes Mellitus Subgroups by Ahlqvist for Achievement of Individualized Treatment Approaches for greater DM Control from Initiation and Avoidance of End Stage Damage

Kulvinder Kochar Kaur*, Gautam Allahbadia, Mandeep Singh

Type2 Diabetes mellitus (T2D) refers to a syndrome that by definition is secondary to numerous extents of βcells failure in addition to reduction in insulin sensitivity. Despite, a lot of metabolic Impairment, most patients are classified as either presenting with T1D or T2D. Recently Ahlqvist et al. posited a new system of classification for adult onset disease, keeping in view the heterogenic metabolic phenotypes of this disease. This new classification system might possess the potential for utilization for greater individualization of treatment depending on the underlying metabolic Impairments in this disease; despite no existing medication studies have developed data to validate this claim. Thus here we provide a brief introduction on the etiopathogenesis with regard to T2D as well as in patients acquiring Diabetes at adult age, besides summarize the evolution of classification systems including one we had earlier provided. Subsequently we try to review the actions of various antidiabetic agents on insulin sensitivity along with β cell function in addition to the posited approaches for individualized therapy as per the various subgroups based on Ahlqvist etal’s posit. Thus we conclude that the innovative T2D subgroups add to an intriguing model that could stimulate us to get better insight over the pathophysiology of this very wide group of T2D that aids in individualized treatment options on the basis of the underlying etiology of the disease. In these innovative T2D subgroups of adult onset disease that would aid in giving some antidiabetic agents that would prove are more advantageous for certain subgroups, considering the major pathophysiology in addition to avoidance of end organ injury. To start with it is just the initiation of trying to get in individualized therapy for T2D, along with studies that start performing evaluation of the current existence in addition to innovative drugs, prospectively in various subgroups possessing separate metabolic phenotypes to succeed in making therapy more individualized.